Details

Autor(en) / Beteiligte

• Tilz, Roland Richard
• Fink, Thomas
• Bartus, Krzysztof
• Wong, Tom
• Vogler, Julia
• Nentwich, Karin
• Panniker, Sandeep
• Fang, Qizhi
• Piorkowski, Christopher
• Liosis, Spyridon
• Gaspar, Thomas
• Sawan, Noureddin
• Metzner, Andreas
• Nietlispach, Fabian
• Maisano, Francesco
• Lee, Randall J
• Foran, John P
• Ouyang, Feifan
• Sievert, Horst
• Deneke, Thomas
• Kuck, Karl-Heinz

Titel

A collective European experience with left atrial appendage suture ligation using the LARIAT+ device

Ist Teil von

• Europace (London, England), 2020-06, Vol.22 (6), p.924-931

Ort / Verlag

England: Oxford University Press

Erscheinungsjahr

2020

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• Abstract Aims We report the collective European experience of percutaneous left atrial appendage (LAA) suture ligation using the recent generation LARIAT+ suture delivery device. Methods and results A total of 141 patients with non-valvular atrial fibrillation and contraindication to oral anticoagulation (OAC), thrombo-embolic events despite OAC or electrical LAA isolation were enrolled at seven European hospitals to undergo LAA ligation. Patients were followed up by clinical visits and transoesophageal echocardiography (TOE) following LAA closure. Left atrial appendage ligation was completed in 138/141 patients (97.8%). Three patients did not undergo attempted deployment of the LARIAT device due to pericardial adhesion after previous epicardial ventricular tachycardia ablation (n = 1), a pericardial access-related complication (n = 1), and multiple posterior LAA lobes (n = 1). Serious 30-day procedural adverse events occurred in 4/141 patients (2.8%). There were two device-related LAA perforations (1.4%) not resulting in any corrective intervention as the LAA was completely sealed with the LARIAT. Minor adverse events occurred in 19 patients (13.5%), including two pericardial effusions due to procedure-related pericarditis requiring pericardiocentesis. Transoesophageal echocardiography was performed after LAA ligation in 103/138 patients (74.6%) after a mean of 181 ± 72 days. Complete LAA closure was documented in 100 patients (97.1%). Two patients (1.8% of patients with follow-up) experienced a transient ischaemic attack at 4 and 7 months follow-up, although there was no leak observed with TOE. There were two deaths during long-term follow-up which were both not device related. Conclusion Initial experience with the LARIAT+ device demonstrates feasibility of LAA exclusion. Further larger prospective studies with longer follow-up are warranted.